Fig 1: Hpca knockdown suppresses NMDA receptor-associated gene expression and impairs NMDA receptor-mediated calcium signaling in mouse hippocampal neural precursor cells (mHNPCs). (A) Representative Western blot images confirming efficient Hpca knockdown in mHNPCs, together with quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of the relative mRNA expression levels of Hpca, Grin2C, Shank1, and Serpine 2. HPCA protein levels were markedly reduced in Hpca shRNA-treated cells compared with control shRNA-treated cells. Consistent with this, the expression levels of NMDA receptor-associated genes were significantly decreased following Hpca knockdown. Calnexin was used as a loading control for Western blot analysis. qRT-PCR data represent the mean ± SEM of three independent experiments. * p < 0.05. (B,C) Representative traces of NMDA receptor-mediated calcium responses in control (B) and Hpca-knockdown (C) mHNPCs. Cells were stimulated with 50 mM KCl and 100 μM NMDA, and intracellular calcium changes were monitored using calcium imaging. Traces shown are representative of 30–50 analyzed cells per condition across at least three independent biological replicates, with consistent results observed across experiments. Hpca knockdown resulted in a substantial reduction in NMDA-induced calcium influx. (D) Quantification of NMDA receptor-mediated calcium influx amplitude in control and Hpca shRNA-treated mHNPCs, demonstrating a significant reduction in NMDA receptor-mediated calcium influx following Hpca knockdown. Calcium responses were quantified as ΔF/F0 values measured at the soma of individual cells. For each biological replicate (n = 3), mean ΔF/F0 values were calculated and subsequently averaged across replicates. Data represent mean ± SEM from at least three independent biological replicates, with 30–50 cells analyzed per condition per replicate. *** p < 0.001. (E) NMDA receptor-mediated calcium responses normalized to KCl-induced depolarization responses, showing a selective impairment of NMDA receptor activity in Hpca-knockdown cells. Normalized values were calculated from the same analyzed cells described in (D) and averaged across at least three independent biological replicates.
Fig 2: Elavl3 knockdown impairs NMDA receptor function and neuronal differentiation in mHNPCs. (A) Representative Western blot images and qRT-PCR analysis showing reduced expression of NMDA receptor-associated proteins and genes in mHNPCs following Elavl3 knockdown. Protein and mRNA levels were normalized to loading or housekeeping controls, respectively. Data represent mean ± SEM from three independent experiments. * p < 0.05. (B) Representative traces of NMDA receptor-mediated intracellular calcium responses in control shRNA (left) and Elavl3 shRNA (right) mHNPCs. Cells were sequentially stimulated with 50 mM KCl and 100 μM NMDA, and changes in intracellular calcium levels were monitored using calcium imaging. Traces shown are representative of 30–50 analyzed cells per condition across at least three independent biological replicates, with consistent results observed across experiments. (C) Quantification of NMDA-induced calcium response amplitudes in control and Elavl3 shRNA-treated mHNPCs, demonstrating a significant reduction in NMDA receptor-mediated calcium signaling following Elavl3 knockdown. (D) Calcium responses were quantified as ΔF/F0 values measured at the soma of individual cells. Data represent mean ± SEM from at least three independent biological replicates (n = 3), with 30–50 cells analyzed per condition per replicate. *** p < 0.001. (E) Immunofluorescence images showing the distribution of TUJ1 (red) and MAP2 (green) in control, Hpca shRNA-treated, and Elavl3 shRNA-treated mHNPCs. Nuclei were counterstained with DAPI (blue). Images shown are representative of at least three independent biological replicates. Scale bar = 100 μm. (F,G) Quantification of TUJ1-positive (F) and MAP2-positive (G) cells following Hpca or Elavl3 knockdown. The percentage of marker-positive cells was calculated from at least five randomly selected fields per condition per biological replicate, with a minimum of 200 cells analyzed per condition. Data represent mean ± SEM from three independent biological replicates (n = 3). * p < 0.05.
Fig 3: Hippocampal Hpca knockdown induces behavioral alterations in mice. (A) Schematic overview of the experimental design. Lentiviral shRNA targeting Hpca (lenti-shHpca) or control shRNA (lenti-shCtr) was stereotaxically infused into the dentate gyrus (DG) of the hippocampus. Behavioral assessments were conducted four weeks after viral infusion, including the open field test (OFT), contextual fear conditioning test, novelty-suppressed feeding test (NSFT), and forced swim test (FST). (B) Representative fluorescence images showing GFP expression (green) in the hippocampal DG following lentiviral infusion, confirming successful viral transduction. Nuclei were counterstained with DAPI (blue). Scale bar = 100 μm. (C) Representative Western blot analysis of HPCA protein levels in hippocampal tissue from lenti-shCtr- and lenti-shHpca-injected mice, demonstrating effective Hpca knockdown in vivo. (D) Quantification of locomotor activity in the OFT, measured as mean movement speed, showing increased locomotor activity in lenti-shHpca-treated mice compared with control mice. (E) Contextual fear conditioning test results showing reduced freezing time in lenti-shHpca-treated mice relative to controls. (F) NSFT results showing a decreased latency to feed in mice with hippocampal Hpca knockdown compared with control mice. (G) FST results showing reduced immobility time in lenti-shHpca-treated mice relative to controls. Data represent mean ± SEM. Each symbol represents an individual mouse; n = 10-11 mice per group. Statistical significance was determined using appropriate parametric tests; ** p < 0.01, *** p < 0.001.
Fig 4: HPCA knockdown alters Elavl3 expression and disrupts the association of Elavl3 mRNA with HPCA-containing complexes in mHNPCs. (A) qRT-PCR analysis showing reduced mRNA expression levels of Hpca and Elavl3 in mHNPCs following Hpca knockdown. Representative Western blot images further confirm the decreased protein levels of HPCA and ELAVl3 under Hpca shRNA-treated conditions. Data represent the mean ± SEM of three independent experiments. * p < 0.05. (B) Schematic illustration of the RNA immunoprecipitation (RIP) assay used to isolate HPCA-associated RNA complexes form mHNPCs using HPCA-specific antibody. (C,D) qRT-PCR analysis of Hpca (C) and Elavl3 (D) mRNA levels detected in HPCA immunoprecipitates. Hpca knockdown resulted in a significant reduction in the enrichment of both Hpca and Elavl3 mRNAs in HPCA-containing complexes compared with control shRNA conditions. Data represent the mean ± SEM from three independent experiments. * p < 0.05.
Supplier Page from OriGene Technologies for Hpca Mouse shRNA Plasmid (Locus ID 15444)